glp 1 agonist in heart failure GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms Results of cardiovascular outcomes trials
Description
"Efficacy and Safety of Retatrutide in Adults with Obesity." NEJM
However, despite the anti-diabetic and anti-obesity functions, of these dual and triple agonists, the long-term safety, cardiovascular, and renal benefits of these multi-target therapies need further validation
ZhuSHuangZChenXJiangWZhouYZhengBet al
The considerable enzyme affinity implies a longer pharmacodynamic effect of this compound, with its short plasma half-lives that may not require dose adjustments in patients with renal dysfunction [32]
